FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161694781> ?p ?o ?g. }

• W3161694781 abstract "ABSTRACT Background Covid-19 vaccines are urgently needed, especially against emerging variants. NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 rS) nanoparticle vaccine containing trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant. Methods A phase 3, randomized, observer-blinded, placebo-controlled trial was conducted in adults 18-84 years old who received two intramuscular 5-µg doses, 21 days apart, of NVX-CoV2373 or placebo (1:1) across 33 sites in the United Kingdom. The primary efficacy endpoint was virologically confirmed symptomatic Covid-19 with onset 7 days after second vaccination in serologically negative participants. Results A total of 15,187 participants were randomized, of whom 7569 received NVX-CoV2373 and 7570 received placebo; 27.2% were 65 years or older, 44.7% had comorbidities and 4.2% had baseline serological evidence of SARS-CoV-2. There were 10 cases of Covid-19 among NVX-CoV2373 recipients and 96 cases among placebo recipients, with symptom onset at least 7 days after second vaccination; NVX-CoV2373 was 89.7% (95% confidence interval, 80.2 to 94.6) effective in preventing Covid-19, with no hospitalizations or deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of 96.4% (73.8 to 99.5) and 86.3% (71.3 to 93.5) against the prototype strain and B.1.1.7 variant, respectively. Vaccine efficacy was similar across subgroups, including participants with comorbidities and those ≥65 years old. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups. Conclusion A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.1.7 variant, and had a reassuring safety profile. (Funded by Novavax, Inc. EudraCT number, 2020-004123-16)." @default.
• W3161694781 created "2021-05-24" @default.
• W3161694781 creator A5001065613 @default.
• W3161694781 creator A5003579475 @default.
• W3161694781 creator A5005196121 @default.
• W3161694781 creator A5005551023 @default.
• W3161694781 creator A5006897859 @default.
• W3161694781 creator A5007218791 @default.
• W3161694781 creator A5007876312 @default.
• W3161694781 creator A5008564110 @default.
• W3161694781 creator A5015357500 @default.
• W3161694781 creator A5016041349 @default.
• W3161694781 creator A5017567807 @default.
• W3161694781 creator A5017703523 @default.
• W3161694781 creator A5020737425 @default.
• W3161694781 creator A5021417237 @default.
• W3161694781 creator A5021615272 @default.
• W3161694781 creator A5021877207 @default.
• W3161694781 creator A5023252020 @default.
• W3161694781 creator A5023735316 @default.
• W3161694781 creator A5025016840 @default.
• W3161694781 creator A5025936000 @default.
• W3161694781 creator A5030714298 @default.
• W3161694781 creator A5032205997 @default.
• W3161694781 creator A5034828137 @default.
• W3161694781 creator A5035682991 @default.
• W3161694781 creator A5038227072 @default.
• W3161694781 creator A5043060669 @default.
• W3161694781 creator A5045509610 @default.
• W3161694781 creator A5046673368 @default.
• W3161694781 creator A5046896957 @default.
• W3161694781 creator A5049618362 @default.
• W3161694781 creator A5057141298 @default.
• W3161694781 creator A5061996545 @default.
• W3161694781 creator A5064019967 @default.
• W3161694781 creator A5072739448 @default.
• W3161694781 creator A5074335409 @default.
• W3161694781 creator A5074394976 @default.
• W3161694781 creator A5077234033 @default.
• W3161694781 creator A5079274076 @default.
• W3161694781 creator A5080001808 @default.
• W3161694781 creator A5084469785 @default.
• W3161694781 creator A5085929559 @default.
• W3161694781 creator A5086644818 @default.
• W3161694781 creator A5088693632 @default.
• W3161694781 creator A5090052989 @default.
• W3161694781 creator A5090468155 @default.
• W3161694781 date "2021-05-14" @default.
• W3161694781 modified "2023-10-14" @default.
• W3161694781 title "Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant" @default.
• W3161694781 cites W3014067025 @default.
• W3161694781 cites W3081892744 @default.
• W3161694781 cites W3111255098 @default.
• W3161694781 cites W3111590711 @default.
• W3161694781 cites W3132370527 @default.
• W3161694781 cites W3133758295 @default.
• W3161694781 cites W3134141435 @default.
• W3161694781 cites W3134566701 @default.
• W3161694781 cites W4205483821 @default.
• W3161694781 doi "https://doi.org/10.1101/2021.05.13.21256639" @default.
• W3161694781 hasPublicationYear "2021" @default.
• W3161694781 type Work @default.
• W3161694781 sameAs 3161694781 @default.
• W3161694781 citedByCount "11" @default.
• W3161694781 countsByYear W31616947812021 @default.
• W3161694781 countsByYear W31616947812022 @default.
• W3161694781 countsByYear W31616947812023 @default.
• W3161694781 crossrefType "posted-content" @default.
• W3161694781 hasAuthorship W3161694781A5001065613 @default.
• W3161694781 hasAuthorship W3161694781A5003579475 @default.
• W3161694781 hasAuthorship W3161694781A5005196121 @default.
• W3161694781 hasAuthorship W3161694781A5005551023 @default.
• W3161694781 hasAuthorship W3161694781A5006897859 @default.
• W3161694781 hasAuthorship W3161694781A5007218791 @default.
• W3161694781 hasAuthorship W3161694781A5007876312 @default.
• W3161694781 hasAuthorship W3161694781A5008564110 @default.
• W3161694781 hasAuthorship W3161694781A5015357500 @default.
• W3161694781 hasAuthorship W3161694781A5016041349 @default.
• W3161694781 hasAuthorship W3161694781A5017567807 @default.
• W3161694781 hasAuthorship W3161694781A5017703523 @default.
• W3161694781 hasAuthorship W3161694781A5020737425 @default.
• W3161694781 hasAuthorship W3161694781A5021417237 @default.
• W3161694781 hasAuthorship W3161694781A5021615272 @default.
• W3161694781 hasAuthorship W3161694781A5021877207 @default.
• W3161694781 hasAuthorship W3161694781A5023252020 @default.
• W3161694781 hasAuthorship W3161694781A5023735316 @default.
• W3161694781 hasAuthorship W3161694781A5025016840 @default.
• W3161694781 hasAuthorship W3161694781A5025936000 @default.
• W3161694781 hasAuthorship W3161694781A5030714298 @default.
• W3161694781 hasAuthorship W3161694781A5032205997 @default.
• W3161694781 hasAuthorship W3161694781A5034828137 @default.
• W3161694781 hasAuthorship W3161694781A5035682991 @default.
• W3161694781 hasAuthorship W3161694781A5038227072 @default.
• W3161694781 hasAuthorship W3161694781A5043060669 @default.
• W3161694781 hasAuthorship W3161694781A5045509610 @default.
• W3161694781 hasAuthorship W3161694781A5046673368 @default.
• W3161694781 hasAuthorship W3161694781A5046896957 @default.
• W3161694781 hasAuthorship W3161694781A5049618362 @default.
• W3161694781 hasAuthorship W3161694781A5057141298 @default.
• W3161694781 hasAuthorship W3161694781A5061996545 @default.

• next